

## Ruxolitinib, JAK inhibitor

Catalog	Unit
TBI4511-5MG	5 mg
TBI4511-25MG	25 mg

### Product Details

**Formal Name:**  $\beta$ R-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile

**Alternate Names:** INCB 018424

**Molecular Formula:** C<sub>17</sub>H<sub>18</sub>N<sub>6</sub>

**Formula Weight:** 306.37

**CAS Number:** 941678-49-5


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).

**Storage:** -20°C

**Stability:**  $\geq$  1 year.



### Applications

JAK inhibitor

### Functions

Potent and selective JAK1&2 inhibitor, IC<sub>50</sub>s=2.7, 4.5 and 322 nM for JAK1, JAK2 and JAK3 respectively. Blocks IL-6 signaling (IC<sub>50</sub>=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC<sub>50</sub>=127 nM). Inhibits the proinflammatory secretome of senescent cells. The JAK1 S646P mutant is highly sensitive to ruxolitinib. Clinically useful cancer chemotherapeutic.

### Application Procedures

First dissolved in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.

**For research use only.**